OnabotulinumtoxinA for chronic migraine: A real-life multicenter study of 479 patients.

Chronic migraine (CM) is a tough condition to treat, especially with medication-overuse headache (MOH). This study looked at how well onabotulinumtoxin A (BoNT-A) works for CM. Researchers studied 479 Polish patients across 12 headache centers. Most of the patients were women, with an average age of 43.6 years. All participants had already tried at least two oral treatments without success. The effectiveness of BoNT-A was measured after three treatment cycles over nine months. Researchers found that a significant number of patients experienced a reduction in headache days. Specifically, the average monthly headache days decreased from 19.1 to a lower number after treatment. The study also aimed to find factors that could predict which patients would respond best to BoNT-A treatment. Overall, the findings suggest that BoNT-A could be a valuable option for chronic migraine patients. Clinical relevance: This research indicates that onabotulinumtoxin A is effective for chronic migraine patients, potentially improving treatment outcomes for those who have not responded to other therapies.